--:--:--LOCAL ·--:--UTC
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    US EQUITIESLAST CLOSE
    AAPL$349.21-0.92%
    MSFT$498.30-1.97%
    GOOGL$272.66-3.46%
    AMZN$257.37-3.87%
    NVDA$145.98-3.30%
    META$596.22-3.27%
    TSLA$374.41-2.43%
    NFLX$58.46-2.27%
    BRK.B$572.04-0.45%
    AVGO$346.65-2.09%
    DIS$120.25-1.72%
    SBUX$104.47-4.25%
    MCD$272.35-0.61%
    NKE$34.33-5.45%
    COST$1093.83-0.25%
    WMT$126.04-1.04%
    HD$336.68-0.28%
    KO$96.09-2.04%
    PG$167.85-1.43%
    ORCL$110.57-2.92%
    CRM$183.31-3.72%
    ADBE$221.68-2.00%
    AMD$489.19-7.72%
    INTC$55.72+1.92%
    QCOM$162.01+1.38%
    CSCO$94.70-2.55%
    IBM$223.88-2.03%
    UBER$65.60-4.60%
    ABNB$172.79-4.12%
    SHOP$131.97-5.34%
    PYPL$56.37-2.63%
    COIN$108.87-1.48%
    PLTR$153.68-1.91%
    HOOD$68.65-0.75%
    JPM$320.22-1.20%
    V$402.25-3.12%
    MA$626.50-2.62%
    BAC$48.57-0.70%
    GS$847.53-2.94%
    LLY$1351.12-2.29%
    UNH$330.48-5.55%
    JNJ$267.14-2.04%
    PFE$27.54-1.85%
    XOM$158.93-1.03%
    BA$160.51-1.47%
    BABA$83.31-1.26%
    TSM$352.09-2.90%
    Plug stock market data into your AI agent — one command: Get your free API key →
    LoginGet API Key
    Company data coverage · NYSE

    CRL — Charles River Laboratories

    Data coverage, completeness and provenance for Charles River Laboratories in the Stock Market API — Health Care · Diagnostics & Research.

    NYSE USA S&P 500
    Core-field completeness
    82.4%
    Statement periods
    FY2021–FY2025
    Filings archived
    0
    Price collection time
    2026-11-19 22:35 UTC

    Stored price coverage

    Source date: 2026-11-19T21:00:02. Source: yfinance. Collection time is shown separately and does not establish a trade date.

    Recent stored price bars, without investment interpretation
    DateCloseCurrencySourceAdjustment basis
    2026-11-19327.9300USDyfinanceSplit- and dividend-adjusted close
    2026-11-18333.2500USDyfinanceSplit- and dividend-adjusted close
    2026-11-17332.1600USDyfinanceSplit- and dividend-adjusted close
    2026-11-16335.5200USDyfinanceSplit- and dividend-adjusted close
    2026-11-13337.9700USDyfinanceSplit- and dividend-adjusted close

    GET /api/v1/companies/CRL/prices · Price parameters and adjustment semantics

    No archived filings are currently stored for this listing.

    Dataset availability · Handle missing data

    Profile

    Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

    Employees: 18,300 · Website: https://www.criver.com · Profile fields populated: 75%

    Data completeness by statement

    Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/CRL/financials.

    Income statement7/10 fields (70.0%)
    Balance sheet13/14 fields (92.9%)
    Cash flow5/6 fields (83.3%)
    Per-share3/4 fields (75.0%)

    Financial statement coverage (USD)

    Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.

    PeriodPeriod end RevenueNet incomeTotal assetsTotal equity Fields populatedSource
    FY2025 (USD) 2025-12-27 28 sec_edgar
    FY2024 (USD) 2024-12-28 28 sec_edgar
    FY2023 (USD) 2023-12-30 28 sec_edgar
    FY2022 (USD) 2022-12-31 28 sec_edgar
    FY2021 (USD) 2021-12-25 28 sec_edgar

    Get CRL data via the API

    The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.

    Company profile

    Name, sector, industry, HQ, employees, market cap, source-tagged.

    GET /api/v1/companies/CRL

    Financial statements

    Multi-year statements with per-field source tags and completeness.

    GET /api/v1/companies/CRL/financials

    Computed ratios

    P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.

    GET /api/v1/companies/CRL/metrics/summary

    News & announcements

    Dated press releases and announcements with source links.

    GET /api/v1/companies/CRL/news

    Quick start

    Create a free key, then:

    curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/CRL

    Query CRL programmatically

    Free tier — instant API key. Built for AI agents.

    Frequently Asked Questions

    What data does the API provide for CRL?
    Stored coverage for CRL: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/CRL; inspect available source metadata for provenance.
    How complete is CRL's financial data?
    The anchor reporting period (FY2025) has 82.4% of the 17 core statement fields populated. Primary source: sec_edgar.
    What reporting periods are covered for CRL?
    5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/CRL/financials.
    Where does CRL's data come from?
    Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/CRL/financials; missing tags do not establish provenance.